Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Brain Diseases 1

Interventions

Temozolomide 30Radiotherapy 23Filgrastim 12Carmustine 12Irinotecan 11Carboplatin 11Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Etoposide 7Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Vincristine 5Peripheral Blood Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5sargramostim 4motexafin gadolinium 4Topotecan 4Thiotepa 4Paclitaxel 4Melphalan 4Gene Expression Profiling 4Gemcitabine 4Drug Therapy 4Busulfan 4temsirolimus 3etoposide phosphate 3Specimen Handling 3Mass Spectrometry 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Central Nervous System Neoplasms × PF-07284890 × Clear all
NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Pfizer

Phase 1 Terminated
65 enrolled 52 charts
CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡